🩸🔍First question of the month!
Swipe to see the answer and its explanation.
#CMML #ChronicMyelomonocyticLeukemia #Hematology #MyeloidNeoplasms #ClonalHematopoiesis #CHIP #TET2 #SRSF2 #ASXL1 #BoneMarrow #Monocytosis #FlowCytometry #HematologicMalignancies #HemeEd #HemeHub #BloodCancer
🩸Facts about Chronic Myelomonocytic Leukemia:
Disease Biology & Pathogenesis
#CMML #MDS #MPN #Hematology #HematologicMalignancies #ClonalHematopoiesis #CHIP #TET2 #SRSF2 #ASXL1 #MyeloidNeoplasms #MedEd #HemeEd #HemeHub #BloodCancer #MyeloidDisorders #ClinicalHematology
🩸Facts about Multiple Myeloma:
Clinical Efficacy and Survival Outcomes
#MultipleMyeloma #BispecificAntibodies #Immunotherapy #Teclistamab #Elranatamab #Daratumumab #ClinicalTrials #Oncology #HematologicMalignancies #CancerTherapy #HEMEHUB
An overview of #CARTcelltherapy, examining applications in #HematologicMalignancies and #SolidTumors, while highlighting ongoing trials and future directions for effective CAR-T therapies in #AML. @idibaps.bsky.social #medsky
#OpenAccess in #STTT: doi.org/10.1038/s413...
#Medsky🧪 #IDSky #immunosky #virosky #publichealth Individuals with #postcovid / #LongCOVID HZ ( #herpeszoster/ #shingles) had significantly higher risks of developing #hematologicmalignancies & infectious complications.
#Medsky🧪 #IDsky #immunosky #oncosky #publichealth Among ICHs, those with #hematologicmalignancies, particularly #Bcell malignancies and those receiving B-cell depletingtherapies, as #monoclonal antibodies (mAbs) targeting the CD20 #antigen (anti-CD20)
This study shows that purinostat mesylate, a #HDAC inhibitor, has good efficacy & immune-modulating effects in #MultipleMyeloma & #lymphoma, highlighting its potential as an effective therapy for #HematologicMalignancies. #medsky
#STTT #OpenAccess: doi.org/10.1038/s413...
Join the Best of Hematology and Breast Cancer 2025, #Tucson, where Dr. Sharad Khurana, Dr. Sima Ehsani, and other leading experts will explore the latest advancements in the diagnosis and management of #HematologicMalignancies and #BreastCancer.🚀 Register TODAY: buff.ly/mTTdmdo #Medsky
"I research #cancer because I saw how our observations + measurements of the biopsies from patients suffering from #hematologicmalignancies can inform bench research…”
-Dr. Mina Xu
yalecancercenter.org/news-article...
#NCRM25 #unitedbycancerresearch
@theaacr.bsky.social @yalepathology.bsky.social
